Health Cor Management, L.P. Biocryst Pharmaceuticals Inc Transaction History

Health Cor Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $89,709 - $203,295	11,370 Added 4.98%	239,820 $2.54 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $24.8 Million - $42.5 Million	-2,148,680 Reduced 90.39%	228,450 $3.72 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $16.5 Million - $22.8 Million	-1,472,340 Reduced 38.25%	2,377,130 $32.9 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $8.55 Million - $10.6 Million	601,370 Added 18.51%	3,849,470 $55.3 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $15.6 Million - $28.2 Million	-1,638,340 Reduced 33.53%	3,248,100 $51.4 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $36 Million - $66.5 Million	4,886,440 New	4,886,440 $49.7 Million

260

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Health Cor Management, L.P. with notifications on news.